Regulatory Challenges: Is a Surrogate End Point Instead of Overall Survival Enough for Regulatory Approval of (Neo)Adjuvant Cancer Treatment? The Swissmedic Perspective.
Matea PavicAnita WolferQiyu LiArunas GircysStephanie JuritzAndreas WickiThomas CernyUlrich-Peter RohrPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Keyphrases